Clinical Trial Update: A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients [Phase 2]

View source ↗

Summary

A Phase 2a clinical trial is evaluating the safety, tolerability, and efficacy of SNP318 in diabetic macular edema (DME); the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• SNP318

Snippet

Sponsor: SciNeuro | Conditions: Diabetic Macular Edema, DME | Phase 2 | Status: NOT_YET_RECRUITING